Michelle L. Mellion MD
Neurophysiology
Assistant Professor, Neurology, Brown University Program in Medicine
Join to View Full Profile
2 Dudley StSte 555Providence, RI 02905
Phone+1 401-444-3032
Fax+1 401-444-3205
Dr. Mellion is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rhode Island Hospital/Brown University HealthFellowship, Clinical Neurophysiology, 2005 - 2006- Rhode Island Hospital/Brown University HealthResidency, Neurology, 2002 - 2005
- Rhode Island Hospital/Brown University HealthInternship, Internal Medicine, 2001 - 2002
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2001
Certifications & Licensure
RI State Medical License 2005 - 2026
MA State Medical License 2006 - 2025
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Clinical Neurophysiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Publications & Presentations
PubMed
- 13 citationsQuantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis.Michelle L Mellion, Per Widholm, Markus Karlsson, André Ahlgren, Rabi Tawil
Neurology. 2022-08-30 - 18 citationsPhase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagementMichelle Mellion, Lucienne Ronco, Cécile Berends, Lisa Pagan, Sander Brooks
British Journal of Clinical Pharmacology. 2021-05-14 - 416 citationsSafety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
The Lancet. Neurology. 2017-12-01
Press Mentions
PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentApril 5th, 2022
Phase 1 Results Support Losmapimod as FSHD TreatmentMarch 26th, 2020
Fulcrum Therapeutics Announces Phase 1 Clinical Trial ResultsOctober 4th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
